KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Restructuring Costs (2022 - 2024)

Neogenomics (NEO) has disclosed Restructuring Costs for 3 consecutive years, with $2.4 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Restructuring Costs fell 48.8% year-over-year to $2.4 million, compared with a TTM value of $8.8 million through Mar 2024, down 4.33%, and an annual FY2024 reading of $6.7 million, down 39.95% over the prior year.
  • Restructuring Costs was $2.4 million for Q1 2024 at Neogenomics, up from $1.2 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $4.7 million in Q1 2023 and bottomed at $1.2 million in Q4 2023.
  • Average Restructuring Costs over 3 years is $3.0 million, with a median of $2.7 million recorded in 2023.
  • The sharpest move saw Restructuring Costs tumbled 73.32% in 2023, then plummeted 48.8% in 2024.
  • Year by year, Restructuring Costs stood at $4.5 million in 2022, then crashed by 73.32% to $1.2 million in 2023, then surged by 99.0% to $2.4 million in 2024.
  • Business Quant data shows Restructuring Costs for NEO at $2.4 million in Q1 2024, $1.2 million in Q4 2023, and $2.1 million in Q3 2023.